Table 4.
Effect of covariates on prevalence of ST131 in Escherichia coli (multivariable random effects meta-regression model)
| Estimate (SE*) | p Value | |
|---|---|---|
| Intercept | −2.9668 (0.2959) | |
| Study period (per month†) | 0.0140 (0.0023) | <0.0001 |
| Infection or colonisation | <0.0001 | |
| Colonisation | Reference | |
| Infection | 1.1545 (0.2281) | |
| Selection of isolates based on resistance pattern | <0.0001 | |
| No selection on resistance profile | Reference | |
| ESBL/3GC-R | 1.3826 (0.2207) | |
| CRE/CPE | 0.5994 (0.4879) | |
| Other | 0.9058 (0.2709) | |
| Location | <0.0001 | |
| Europe | Reference | |
| North America | 0.4436 (0.1675) | |
| South America | −2.2868 (0.6101) | |
| Australia | −0.4209 (0.3407) | |
| Asia | −0.3657 (0.1927) | |
| Africa | −0.2246 (0.3154) |
*Parameter estimates (SEs) are presented on a logit scale.
†Reference date: 1 January 2009.
CRE/CPE, carbapenem-resistant Enterobacteriaceae/carbapenemase-producing Enterobacteriaceae; ESBL/3GC-R, extended-spectrum β-lactamases/third-generation cephalosporin resistance.